These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 6488409)

  • 41. Use of beta-cyclodextrin fluorophore complexes to improve the efficiency of fluorescent label incorporation into proteins.
    Kinsland LN; Wiechelman KJ
    J Biochem Biophys Methods; 1984 Mar; 9(1):81-3. PubMed ID: 6725851
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of roll mixing with beta-cyclodextrin on enhancing solubilities of water insoluble drugs.
    Nozawa Y; Yamamoto A
    Pharm Acta Helv; 1989; 64(1):24-9. PubMed ID: 2717647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Kinetic study of beta-cyclodextrin-dye system by high-pressure temperature-jump method.
    Nakatani H; Hiromi K
    J Biochem; 1984 Jul; 96(1):69-72. PubMed ID: 6490608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Benzylisoquinoline alkaloid reactions with barbiturates. Reaction of papaverine with sodium phenobarbital. III. Avoidance of incompatibility by using the beta-cyclodextrin inclusion complex].
    Rácz I; Plachy J; Szabóné Tábori M; Stadlerné Szöke A; Vikmon M; Szejtli J
    Acta Pharm Hung; 1984 Jul; 54(4):154-9. PubMed ID: 6485810
    [No Abstract]   [Full Text] [Related]  

  • 45. Solubilization of amphotericin B with gamma-cyclodextrin.
    Vikmon M; Stadler-Szöke A; Szejtli J
    J Antibiot (Tokyo); 1985 Dec; 38(12):1822-4. PubMed ID: 4093341
    [No Abstract]   [Full Text] [Related]  

  • 46. Interaction of beta-cyclodextrin with bile salts in aqueous solutions.
    Miyajima K; Yokoi M; Komatsu H; Nakagaki M
    Chem Pharm Bull (Tokyo); 1986 Mar; 34(3):1395-8. PubMed ID: 3731354
    [No Abstract]   [Full Text] [Related]  

  • 47. [Stabilization and reduction of irritant taste of anti-inflammatory drug pirprofen by beta-cyclodextrin complexation].
    Hibi T; Tatsumi M; Hanabusa M; Higuchi R; Imai T; Otagiri M; Uekama K
    Yakugaku Zasshi; 1984 Sep; 104(9):990-6. PubMed ID: 6335527
    [No Abstract]   [Full Text] [Related]  

  • 48. Inclusion complexes of poorly water-soluble drugs with glucosyl-cyclodextrins.
    Koizumi K; Okada Y; Kubota Y; Utamura T
    Chem Pharm Bull (Tokyo); 1987 Aug; 35(8):3413-8. PubMed ID: 3427720
    [No Abstract]   [Full Text] [Related]  

  • 49. [A structural study of the inclusion compound of piroxicam with beta-cyclodextrin by NMR].
    Miao ZC; Du ZH; Xu GF; Shi TS
    Yao Xue Xue Bao; 1988; 23(9):682-7. PubMed ID: 3256202
    [No Abstract]   [Full Text] [Related]  

  • 50. [Application of beta-cyclodextrin during direct pressing of tablets].
    Szabóné RP; Pintyéné HK; Kun L; Miseta M; Selmeczi B
    Acta Pharm Hung; 1989 May; 59(3):99-107. PubMed ID: 2763849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solute-induced circular dichroism: complexation of achiral drugs with cyclodextrin.
    Han SM; Purdie N
    Anal Chem; 1984 Dec; 56(14):2822-5. PubMed ID: 6524657
    [No Abstract]   [Full Text] [Related]  

  • 52. Use of hydroxypropyl- and hydroxyethyl-derivatized beta-cyclodextrins for the thin-layer chromatographic separation of enantiomers and diastereomers.
    Armstrong DW; Faulkner JR; Han SM
    J Chromatogr; 1988 Oct; 452():323-30. PubMed ID: 3243848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of stability and biological effect on cholecalciferol by beta-cyclodextrin complexation.
    Szejtli J; Bolla-Pusztai E; Szabó P; Ferenczy T
    Pharmazie; 1980 Dec; 35(12):779-87. PubMed ID: 6259671
    [No Abstract]   [Full Text] [Related]  

  • 54. Development of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins.
    Brewster ME; Estes KS; Bodor N
    J Parenter Sci Technol; 1989; 43(6):262-5. PubMed ID: 2600731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improving the aqueous stability of prostaglandin E2 and prostaglandin A2 by inclusion complexation with methylated-beta-cyclodextrins.
    Hirayama F; Kurihara M; Uekama K
    Chem Pharm Bull (Tokyo); 1984 Oct; 32(10):4237-40. PubMed ID: 6597735
    [No Abstract]   [Full Text] [Related]  

  • 56. Distribution of substituents in 2-hydroxypropyl ethers of cyclomaltoheptaose.
    Pitha J; Rao CT; Lindberg B; Seffers P
    Carbohydr Res; 1990 Apr; 200():429-35. PubMed ID: 2379216
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Possible utility of beta-cyclodextrin complexation in the preparation of biphenyl acetic acid suppositories].
    Uekama K; Maeda T; Arima H; Irie T; Hirayama F
    Yakugaku Zasshi; 1986 Dec; 106(12):1126-30. PubMed ID: 3559906
    [No Abstract]   [Full Text] [Related]  

  • 58. Analysis of interfacial transfer and absorption behavior of drugs following dissolution from beta-cyclodextrin complexes.
    Uekama K; Uemura Y; Irie T; Otagiri M
    Chem Pharm Bull (Tokyo); 1983 Oct; 31(10):3637-43. PubMed ID: 6671224
    [No Abstract]   [Full Text] [Related]  

  • 59. [Enhancement of drug absorption with cyclodextrin inclusion complexes].
    Szejtli J; Gerlóczy A; Szente L; Bánky-Elöd E; Sebestyén G; Fónagy A; Kurcz M
    Acta Pharm Hung; 1979 Sep; 49(5):207-21. PubMed ID: 532664
    [No Abstract]   [Full Text] [Related]  

  • 60. Separation of drug stereoisomers by the formation of beta-cyclodextrin inclusion complexes.
    Armstrong DW; Ward TJ; Armstrong RD; Beesley TE
    Science; 1986 May; 232(4754):1132-5. PubMed ID: 3704640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.